Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Market Cap	54.28B
Revenue (ttm)	51.13M -11.1%
Net Income	-416.66M
EPS	-7.40
Shares Out	325.98M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,662,014
Average Volume	683,018
Open	148.80
Previous Close	148.80
Day's Range	142.00 - 166.50
52-Week Range	56.00 - 166.50
Beta	n/a
RSI	86.89
Earnings Date	n/a

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd. operates as a clinical-stage biotechnology company. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs in Mainland China, Hong Kong, Macau, and Taiwan. Its products include KJ017, a recombinant human hyaluronidase; KJ103, an recombinant immunoglobulin G (IgG)-degrading enzyme; SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH-CTP); BJ044, a recombinant ulinastatin developed through synthetic biology;...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Employees: 348
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2659

Financial Performance

Financial numbers in CNY